PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 34 filers reported holding PHARVARIS N V in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,743,013 | +37.8% | 1,329,325 | 0.0% | 2.05% | +31.8% |
| Q2 2023 | $20,125,981 | +87.8% | 1,329,325 | 0.0% | 1.56% | +119.9% |
| Q1 2023 | $10,714,360 | -19.8% | 1,329,325 | +12.0% | 0.71% | -15.2% |
| Q4 2022 | $13,357,204 | +185.5% | 1,187,307 | +94.6% | 0.83% | +274.0% |
| Q3 2022 | $4,679,000 | -59.2% | 610,000 | +17.5% | 0.22% | -60.5% |
| Q2 2022 | $11,477,000 | +22.5% | 519,339 | +0.6% | 0.56% | +14.4% |
| Q1 2022 | $9,366,000 | +26.1% | 516,321 | 0.0% | 0.49% | +40.3% |
| Q4 2021 | $7,430,000 | +0.0% | 516,321 | +23.2% | 0.35% | -8.3% |
| Q3 2021 | $7,428,000 | +258.7% | 418,943 | +276.9% | 0.38% | +317.4% |
| Q2 2021 | $2,071,000 | +48.0% | 111,144 | +122.3% | 0.09% | +58.6% |
| Q1 2021 | $1,399,000 | – | 50,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $60,770,000 | 8.21% |
| venBio Partners LLC | 2,303,310 | $42,911,000 | 5.06% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59,255,000 | 3.88% |
| Foresite Capital Management V, LLC | 364,142 | $6,784,000 | 2.67% |
| VR Adviser, LLC | 902,882 | $16,821,000 | 2.04% |
| Cormorant Asset Management, LP | 744,863 | $13,634,000 | 0.46% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,032,757 | $19,240,000 | 0.34% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $45,087,000 | 0.32% |
| Opaleye Management Inc. | 79,837 | $1,487,000 | 0.25% |
| Avidity Partners Management LP | 400,000 | $7,452,000 | 0.20% |